ATE458732T1 - Verwendung von 4-imidazol-derivaten für zns- erkrankungen - Google Patents

Verwendung von 4-imidazol-derivaten für zns- erkrankungen

Info

Publication number
ATE458732T1
ATE458732T1 AT07703939T AT07703939T ATE458732T1 AT E458732 T1 ATE458732 T1 AT E458732T1 AT 07703939 T AT07703939 T AT 07703939T AT 07703939 T AT07703939 T AT 07703939T AT E458732 T1 ATE458732 T1 AT E458732T1
Authority
AT
Austria
Prior art keywords
imidazole derivatives
cns diseases
cns
diseases
imidazole
Prior art date
Application number
AT07703939T
Other languages
English (en)
Inventor
Guido Galley
Zbinden Katrin Groebke
Marius Hoener
Roger Norcross
Henri Stalder
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE458732T1 publication Critical patent/ATE458732T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT07703939T 2006-01-27 2007-01-17 Verwendung von 4-imidazol-derivaten für zns- erkrankungen ATE458732T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06100938 2006-01-27
PCT/EP2007/050441 WO2007085556A2 (en) 2006-01-27 2007-01-17 Use of 4-imidazole derivatives for cns disorders

Publications (1)

Publication Number Publication Date
ATE458732T1 true ATE458732T1 (de) 2010-03-15

Family

ID=38051581

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07703939T ATE458732T1 (de) 2006-01-27 2007-01-17 Verwendung von 4-imidazol-derivaten für zns- erkrankungen

Country Status (18)

Country Link
US (1) US8158668B2 (de)
EP (1) EP1981880B1 (de)
JP (1) JP2009524616A (de)
KR (1) KR101079914B1 (de)
CN (1) CN101374832B (de)
AR (1) AR059206A1 (de)
AT (1) ATE458732T1 (de)
AU (1) AU2007209380B2 (de)
BR (1) BRPI0706759A2 (de)
CA (1) CA2637308C (de)
DE (1) DE602007004949D1 (de)
ES (1) ES2338716T3 (de)
IL (1) IL192885A0 (de)
NO (1) NO20083356L (de)
RU (1) RU2008130448A (de)
TW (1) TW200738645A (de)
WO (1) WO2007085556A2 (de)
ZA (1) ZA200806457B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2637312A1 (en) 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of substituted 2-imidazole of imidazoline derivatives
MX2009003801A (es) * 2006-10-19 2009-04-22 Hoffmann La Roche Aminometil-4-imidazoles.
CA2675221C (en) 2007-02-02 2016-02-23 F. Hoffmann-La Roche Ag Novel 2-aminooxazolines as taar1 ligands
MX2009008776A (es) 2007-02-13 2009-08-25 Schering Corp Agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos.
BRPI0807961A2 (pt) 2007-02-13 2017-05-16 Pharmacopeia Llc agonista de alfa2c adrenorreceptor funcionalmente seletivos.
WO2008100459A1 (en) 2007-02-13 2008-08-21 Schering Corporation Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
BRPI0812833A2 (pt) * 2007-07-03 2014-12-09 Hoffmann La Roche 4-imidazolinas e seu uso como antidepressivos
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
EP2250153B1 (de) * 2008-01-18 2013-06-19 Allergan, Inc. (substituiertes aryl-(imidazol)-methyl)-phenylverbindungen als untertypselektive modulatoren der adrenergen alpha-2b- und/oder alpha-2c-rezeptoren
ES2556633T3 (es) * 2008-07-24 2016-01-19 F. Hoffmann-La Roche Ag Derivados de 4,5-dihidro-oxazol-2-ilo
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
US20120190719A1 (en) * 2009-08-26 2012-07-26 Allergan, Inc. Methods of treating motor disorders with alpha-2b andrenergic receptor agonists
AR077969A1 (es) 2009-08-31 2011-10-05 Abbott Healthcare Products Bv Derivados de (tio)morfolina comomoduladores de s1p
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
AR090557A1 (es) 2012-04-02 2014-11-19 Orion Corp DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
CA2903979A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
TWI709417B (zh) 2013-10-07 2020-11-11 美商帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
KR101891185B1 (ko) 2013-10-07 2018-08-24 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물
RU2646512C2 (ru) 2013-10-07 2018-03-05 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
CN103664788B (zh) * 2013-12-04 2015-11-25 湖北生物医药产业技术研究院有限公司 制备美托咪啶的方法
WO2017134053A1 (en) 2016-02-04 2017-08-10 Chiesi Farmaceutici S.P.A. Pyrazole derivatives as phosphoinositide 3-kinases inhibitors
RS60825B1 (sr) 2016-03-17 2020-10-30 Hoffmann La Roche Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a
CN105884691B (zh) * 2016-06-02 2017-08-25 江苏恒瑞医药股份有限公司 一种制备右美托咪定及其中间体的方法
KR20190060007A (ko) 2016-10-31 2019-05-31 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
WO2018209267A2 (en) * 2017-05-12 2018-11-15 Board Of Trustees Of The Southern Illinois University On Behalf Of Southern Illinois University Edwardsville 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
CN107879979B (zh) * 2017-10-27 2020-08-25 广东莱佛士制药技术有限公司 一种右美托咪定的制备方法
MX2022005084A (es) 2019-10-31 2022-05-26 Escape Bio Inc Formas sólidas de un modulador del receptor s1p a.
WO2024240240A1 (zh) * 2023-05-24 2024-11-28 江苏恩华药业股份有限公司 一种咪唑衍生物、中间体、制备方法及其应用
CN121511240A (zh) * 2023-06-19 2026-02-10 江苏恩华药业股份有限公司 一种取代咪唑衍生物、中间体、制备方法及其应用
WO2025162115A1 (zh) * 2024-02-04 2025-08-07 成都麻沸散医药科技有限公司 一种杂环化合物及其制药用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7312245A (nl) 1973-09-06 1975-03-10 Stamicarbon Werkwijze voor het bereiden van alphamethylstyreen bevattende blokcopolymeren.
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
GB2101114B (en) * 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
JPH0733333B2 (ja) * 1986-12-12 1995-04-12 三井石油化学工業株式会社 脳機能改善薬
GB2215206B (en) * 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
FI894911A0 (fi) * 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
GB2256135B (en) 1991-05-31 1995-01-18 Orion Yhtymae Oy Transdermal administration of 4-substituted imidazoles
GB9521680D0 (en) 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
PT1036065E (pt) * 1997-12-04 2004-09-30 Allergan Inc Derivados de imidazol substituidos com actividade do tipo agonista nos receptores alfa 2b ou 2b/2c adrenergicos
US6573289B1 (en) * 1998-04-23 2003-06-03 Takeda Chemical Industries, Ltd. Naphthalene derivatives, their production and use
JP4546589B2 (ja) * 1998-04-23 2010-09-15 武田薬品工業株式会社 ナフタレン誘導体
JP4520012B2 (ja) * 1999-10-22 2010-08-04 武田薬品工業株式会社 １−置換−１−（１ｈ−イミダゾール−４−イル）メタノール類
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
IL147921A0 (en) 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
KR100768609B1 (ko) * 2003-07-09 2007-10-18 에프. 호프만-라 로슈 아게 티오페닐아미노이미다졸린
EP1663311A2 (de) * 2003-09-12 2006-06-07 Allergan, Inc. Verfahren und zusammensetzungen zur behandlung von schmerzen und anderer alpha-2-adrenerg vermittelter erkrankungen
EP1797043A1 (de) * 2004-09-24 2007-06-20 Allergan, Inc. 4-(phenylmethyl und substituiertes phenylmethyl)imidazol-2-thione, die als spezifische alpha2-adrenerge agonisten wirken

Also Published As

Publication number Publication date
AR059206A1 (es) 2008-03-19
KR101079914B1 (ko) 2011-11-04
AU2007209380A1 (en) 2007-08-02
WO2007085556A3 (en) 2007-10-04
EP1981880A2 (de) 2008-10-22
AU2007209380B2 (en) 2011-12-08
IL192885A0 (en) 2009-02-11
CN101374832A (zh) 2009-02-25
JP2009524616A (ja) 2009-07-02
CA2637308A1 (en) 2007-08-02
DE602007004949D1 (de) 2010-04-08
ES2338716T3 (es) 2010-05-11
TW200738645A (en) 2007-10-16
CA2637308C (en) 2014-02-25
US8158668B2 (en) 2012-04-17
BRPI0706759A2 (pt) 2011-04-05
KR20080088658A (ko) 2008-10-02
NO20083356L (no) 2008-10-21
ZA200806457B (en) 2009-11-25
US20070197622A1 (en) 2007-08-23
CN101374832B (zh) 2013-03-06
EP1981880B1 (de) 2010-02-24
WO2007085556A2 (en) 2007-08-02
RU2008130448A (ru) 2010-03-10

Similar Documents

Publication Publication Date Title
DE602007004949D1 (de) Verwendung von 4-imidazol-derivaten für zns-erkrankungen
DE602005021132D1 (de) Ausgabeeinheit für Wertscheine
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
DE602006015297D1 (de) 3-azetidincarbonsäure-derivate zur verwendung als immunsuppressiva
CR10562A (es) Nuevos derivados de piridazina
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
BRPI0719389A2 (pt) Derivados de hidantoína utilizados como inibidores de mmp
CU23828B1 (es) Derivados de dihidropiridina de utilidad como inhibodires de la proteína quinasa
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
HRP20170222T1 (hr) Kristalni oblik karbamoil-cikloheksan derivata
CY2016017I2 (el) Συνθεση για θεραπεια πνευμονικης υπερτασης
MA32551B1 (fr) Nouveaux composes utiles pour le traitement de maladies degeneratives et inflammatoires
DE602006011363D1 (de) Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
ATE528296T1 (de) Polymorphe form von 4-ä3-(4- cyclopropancarbonylpiperazin-1-carbonyl)-4- fluorbenzylü-2h-phthalazin-1-on
DE112007000789A5 (de) Verwendung von Bora-tetraazepentalenen
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
ATE552753T1 (de) Ausziehführung für schubladen
EP2201946A4 (de) Hemmer der pai-1-produktion
NO20083328L (no) Fremgangsmåte for fremstilling av papir
NO20091266L (no) Fremgangsmåter for administrering av langvarige hypoglykemiske midler
EP2242362A4 (de) Iap-hemmer
FI20075505A0 (fi) Menetelmä silmälasien valmistamiseksi
DK1916890T3 (da) Forbedrede egenskaber for græsendofytter
IL192319A (en) Assessment of medical conditions

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1981880

Country of ref document: EP